Long-acting injectables work without oral lead-in period
Islatravir plus doravirine remains effective at 96 weeks
Promising results for programme to reduce sleep disturbance in people with HIV
Weight gain after switch to an integrase inhibitor does not boost 'bad fat'
Injectable HIV therapy should save money if adherence is better than to oral therapies
Weight gain on HIV treatment: what is normal, and what is harmful?
Two-thirds of people living with HIV would like to try injectable treatment, according to European survey
Fatty liver disease common in people living with HIV and hepatitis B
Genetics may contribute to weight gain after switching from efavirenz to an integrase inhibitor
